Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL28746438 | 0.94 | RAB9A (0.56) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL11063346 | 0.88 | TSHR (0.61) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL6354305 | 0.84 | RAB9A (0.57) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL6502006 | 0.84 | RAB9A (0.57) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL31344419 | 0.84 | RAB9A (0.57) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL4586692 | 0.83 | TDP1 (0.63) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL582352 | 0.83 | TDP1 (0.63) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| SCHEMBL194520 | 0.83 | TDP1 (0.63) | RAB9ANPC1LMNATDP1ALDH1A1 | |
| Anthracene SCHEMBL28077695 | 0.82 | MEN1 (0.47) | RAB9ANPC1TDP1KDM4EKMT2A | |
| SCHEMBL24112404 | 0.82 | RAB9A (0.64) | RAB9ANPC1LMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104419326-A | Slurry composition for chemical mechanical polishing | COWON INNOTECH INC | 2015-03-18 | — | — | CN | claimed |
| CN-119827695-A | Degradation impurity detection method of teprenone capsules | 浙江核力欣健药业有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-113214164-B | Synthetic method of intermediate 2,4-dimethylpyrimidin-5-ol of Lebo Lei Sheng | 广西天铭药业有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| CN-113214164-A | Synthetic method of Leborane intermediate 2, 4-dimethylpyrimidine-5-ol | 广西天铭药业有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-110337308-A | exon skipping oligomer conjugates for muscular dystrophy | 萨勒普塔医疗公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110290812-A | exon skipping oligomer conjugates for muscular dystrophy | 萨勒普塔医疗公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-109563114-A | Process for preparing oligomers | 萨勒普塔医疗公司 | 2019-04-02 | — | — | CN | disclosed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| CN-1038930-C | Azetidinone derivatives useful in preparation of carbapenem antibiotics | SANKYO CO (JP) | 1998-07-01 | — | — | CN | disclosed |
| EP-0646002-A1 | PREPARATION AND USE OF NOVEL CYCLODEXTRIN-BASED DISPERSIBLE NANOVESICULAR COLLOIDAL SYSTEMS IN THE FORM OF NANOCAPSULES. | CENTRE NAT RECH SCIENT (FR) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993025194-A1 | PREPARATION AND USE OF NOVEL CYCLODEXTRIN-BASED DISPERSIBLE NANOVESICULAR COLLOIDAL SYSTEMS IN THE FORM OF NANOCAPSULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1993-12-23 | — | — | WO | disclosed |
| CN-1068108-A | Be used to prepare the aza cyclo-butanone derivatives of carbapenem antibiotics | SANKYO CO (JP) | 1993-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | RAB9A 1686/4885NPC1 1355/4885LMNA 3526/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | RAB9A 1686/4885NPC1 1355/4885LMNA 3526/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | RAB9A 2344/4885NPC1 481/4885LMNA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.